Introduction: Obesity is currently an endemic problem worldwide largely caused by an environment that promotes excessive food consumption and discourages physical activity. The sources of obesity are directly related to two areas: genetic and environmental factors, which constantly interact in the regulation of body weight. Aim: Through this research, it was aimed to evaluate the typical profile of the individual who uses metabolic surgery and the degree of physical and psychological satisfaction after such an intervention. Materials and methods: The patients introduced in the study are from personal cases, in number of about 1130, operated during 9 years. Of these, 122 represented the basis for the analysis and had to answer 37 questions in a preoperative questionnaire and 34 questions in a postoperative one and we extracted 15 questions from each of the questionnaire. Results: Statistics show that there was an improvement in quality of life as reported by 77.78% of interviewers, libido and sexual quality were improved in 44% of the included patients and a level of stress considered responsible for food hyperapetitis in only about 43% of respondents. Conclusions: Improving the quality of life is directly related to weight loss. In addition, there is a correlation between improving the quality of life and improving sex life or increasing the frequency of exercise. Metabolic surgery must be understood with all the benefits it generates.

Vascular tone is generally controlled by both the humoral component and the neuro-vegetative component. Regarding the second one, catecholaminergic sympathetic innervation of blood vessels is almost a rule in the body[1,2].
It is known that the iris is sympathetically inner-vated, both at the level of the iris dilator muscle[1,2] and at the level of iris blood vessels[3]. Cathecolamines are responsible for vasoconstriction and, in some vascular beds, vasodilation. [...]

Histamine and serotonin (5-hydroxytryptamine) are two amino acid derivatives with important biological functions [1]. Histamine, an endogenous monoamine, is synthesized from the histidine and is stored in most tissues and degraded in liver by histaminase. The most important roles of histamine are: mediation of type I allergic reactions, stimulation of stomach secretion of hydrochloric acid and pepsin (as autacoid), and functioning as a neurotransmitter (especially in the central nervous system)[2]. Regarding the vascular effects of histamine in non-ocular territories, there have not been many published literature reviews, for example, there are data reviewed for pulmonary artery[3], brain territory[4], but these data are not recent.

5-HT4 receptors are a G-protein-coupled family of re-ceptors coupled with Gs protein that stimulates the pro-duction of the intracellular signaling molecule cAMP. It has two isoforms (5-HT4S and 5-HT4L), differing in the length and sequence of their C-termini[1]. 5-HT4 are present both in the central nervous system and peripheral tissues
in the brain, are found mostly in basal ganglia and the hippocampus[2]. In the periphery, 5HT4 play an important role in the functioning of gastrointestinal tract, urinary bladder, heart and adrenal gland. Gastrointestinal 5-HT4 receptors potentiate peristalsis, and electrolyte secretion. In the urinary bladder, acti-vation of 5-HT4 receptors modulates cholinergic and purinergic transmission. Stimulation of atrial 5-HT4 receptors produces tachycardia and arrhythmias. In the adrenal gland, activation of 5-HT4 receptors releases cortisol, aldosterone and corticosterone[3]. [...]

Serotonin (5-hydroxytryptamine or 5-HT)is a mo-noamine neurotransmitter involved in regulating and modulating physiological and behavioral processes [1]. Serotonin also plays an important role in the functio-ning of enteric nervous system [2]. [...]

Pain is defined by IASP (International Association for the Study of Pain) as an unpleasant sensorial and emotional feeling which is produced by an actual or potential tissue injury. Chronic pain management is currently a major public health challenge throughout the world, especially for patients with oncologic disorders. Data show that up to 90 percent of cancer patients suffer from pain during the course of their illness and 50-80 percent receive an inadequate pain management. [...]

Several studies have suggested an association between depression and inflammation (reviewed in 1, 2, 3, 4). Treatment with pro-inflammatory agents (Calmette-Guerin bacillus, endotoxins) causes depressive symptoms (5, 6, 7). Non-steroidal antiinflammatory agents, NSAIDs, particularly the COX-2 selective ones (e.g., celecoxib) showed promising results in the augmentation of the antidepressant effect in clinical studies on major depression or depressive symptomatology. The antidepressant activity of celecoxib was apparent both in the assessment of the frequency of the remissions, and in the assessment of the therapeutic response (reviewed in 8). Contrary to these studies, there is evidence that NSAIDs decrease the antidepressant effects of the antidepressant drugs. Certain NSAIDs showed depressant effects in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical trial (concomitant administration of NSAIDs and antidepressants was shown to decrease the responder percentage to 45% in major depression, vs. 55% responder percentage when antidepressants were given without NSAIDs) (9). There is experimental evidence of antidepressant effects of NSAIDs in laboratory animals, particularly mice and rats, but also two studies showing that certain NSAIDs have depressant activity when given alone or in association with serotonin-specific reuptake inhibitors, SSRI (9, 10, 11, 12).